TORNADO Trademark

Trademark Overview


On Monday, March 21, 2022, a trademark application was filed for TORNADO with the United States Patent and Trademark Office. The USPTO has given the TORNADO trademark a serial number of 97978188. The federal status of this trademark filing is REGISTERED as of Tuesday, June 18, 2024. This trademark is owned by Cambrian BioPharma, Inc.. The TORNADO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and technological services, namely, pharmaceutical research and design services relating thereto in the nature of pharmaceutical development; pharmaceutical development services; scientific research in the fields of oncology, aging, longevity, autoimmunity, dysregulated nutrient sensing, overactive cell signaling, the mTOR pathway, and mTOR inhibition; pharmaceutical testing, pre-clinical research, and clinical research in the fields of oncology, aging, longevity, autoimmunity, dysregulated nutrient sensing, overactive cell signaling, the mTOR pathway, and mTOR inhibition; medical research; provision of information and consultancy relating to medical and scientific research in the fields of clinical trials, oncology, aging, longevity, autoimmunity, dysregulated nutrient sensing, overactive cell signaling, and the mTOR pathway
tornado

General Information


Serial Number97978188
Word MarkTORNADO
Filing DateMonday, March 21, 2022
Status700 - REGISTERED
Status DateTuesday, June 18, 2024
Registration Number7423564
Registration DateTuesday, June 18, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 18, 2023

Trademark Statements


Goods and ServicesScientific and technological services, namely, pharmaceutical research and design services relating thereto in the nature of pharmaceutical development; pharmaceutical development services; scientific research in the fields of oncology, aging, longevity, autoimmunity, dysregulated nutrient sensing, overactive cell signaling, the mTOR pathway, and mTOR inhibition; pharmaceutical testing, pre-clinical research, and clinical research in the fields of oncology, aging, longevity, autoimmunity, dysregulated nutrient sensing, overactive cell signaling, the mTOR pathway, and mTOR inhibition; medical research; provision of information and consultancy relating to medical and scientific research in the fields of clinical trials, oncology, aging, longevity, autoimmunity, dysregulated nutrient sensing, overactive cell signaling, and the mTOR pathway

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, March 9, 2023
Primary Code042
First Use Anywhere DateWednesday, February 16, 2022
First Use In Commerce DateWednesday, February 16, 2022

Trademark Owner History


Party NameCambrian BioPharma, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Party NameCambrian BioPharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Party NameCambrian BioPharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10003

Trademark Events


Event DateEvent Description
Friday, March 25, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 24, 2022NEW APPLICATION ENTERED
Wednesday, January 4, 2023ASSIGNED TO EXAMINER
Monday, January 9, 2023NON-FINAL ACTION WRITTEN
Thursday, March 2, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 9, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 9, 2023NON-FINAL ACTION E-MAILED
Thursday, March 2, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 2, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 9, 2023EXAMINERS AMENDMENT -WRITTEN
Thursday, March 9, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, March 9, 2023EXAMINERS AMENDMENT E-MAILED
Thursday, March 9, 2023EXAMINER'S AMENDMENT ENTERED
Saturday, March 11, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 18, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 18, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 13, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, November 29, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, November 29, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, November 29, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 12, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, December 12, 2023SOU EXTENSION 1 FILED
Tuesday, December 12, 2023SOU EXTENSION 1 GRANTED
Thursday, December 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 8, 2024TEAS STATEMENT OF USE RECEIVED
Monday, April 8, 2024DIVISIONAL REQUEST RECEIVED
Monday, April 8, 2024TEAS REQUEST TO DIVIDE RECEIVED
Monday, April 29, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, May 8, 2024DIVISIONAL PROCESSING COMPLETE
Monday, April 8, 2024USE AMENDMENT FILED
Wednesday, May 8, 2024STATEMENT OF USE PROCESSING COMPLETE
Tuesday, May 14, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, June 18, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, June 18, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, May 14, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED